Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
4-amino-5-hydroxy-6-(5-{4-chloro-6-[4-(2-sulfonatooxyethanesulfonyl)phenylamino]-1,3,5-triazin-2-ylamino}-2-sulfonatophenylazo)-3-(2-sulfonato-4-(2-sulfonatooxyethanesulfonyl)phenylazo)naphthalene-2,7-disulfonate potassium/sodium;reaction mass of: 4-amino-3-(4-ethenesulfonyl-2-sulfonatophenylazo)-5-hydroxy-6-(5-{4-chloro-6-[4-(2-sulfonatooxyethanesulfonyl)phenylamino]-1,3,5-triazin-2-ylamino}-2-sulfonatophenylazo)naphthalene-2,7-disulfonate potassium/sodium
EC number: 451-440-9 | CAS number: 586372-44-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- June 19 to August 12, 2003
- Reliability:
- 1 (reliable without restriction)
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 003
- Report date:
- 2003
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.7 (Repeated Dose (28 Days) Toxicity (Oral))
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- yes
Test material
- Test material form:
- solid: particulate/powder
- Remarks:
- migrated information: powder
- Details on test material:
- Identity FAT40'815/A
Description dark shining solid powder
Batch number WP 8/03
Purity approx. 75%
Composition Confidential information, available in Sponsor's file.
Stability of test item Stable under storage conditions
Expiry date 01 May 2010
Storage conditions at room temperature (17-23°C) in the original container
away from direct sunlight
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- Test system : Rat, HanBrhWIST (SPF)
Rationale : Recognized by the international guidelines as the recommended test system.
Source : RCC Ltd, Laboratory Animal Services, CH-4414 Füllinsdorf / Switzerland
Total number of animals per group :
Groups 1 and 4: 10 males; 10 females
Groups 2 and 3: 5 males; 5 females
Total number of animals : 30 males and 30 females
Age at delivery: 6 weeks
Body weight range at acclimatization :
Males: 133.2 -156.6 grams (mean 146.6 grams)
Females: 116.4 -130.5 grams (mean 123.7 grams)
Conditions : Standard Laboratory Conditions. Air-conditioned with 10-15 air changes per hour, and continuously monitored environment with a target range for temperature of 22 ± 3 °C and for relative humidity between 30-70 %. 12 hours fluorescent light/12 hours dark, music during the light period.
Accommodation : In groups of five in Makrolon type-4 cages with wire mesh tops and standardized softwood bedding ('Lignocel' Schill AG, CH-4132 Muttenz/Switzerland).
Diet : Pelleted standard Provimi Kliba 3433 (batch no. 17/03 and 40/03) rat maintenance diet (Provimi Kliba AG, CH-4303 Kaiseraugst/ Switzerland) was available ad libitum
Water : Community tap-water from Itingen was available ad libitum in water bottles.
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- other: bidistilled water
- Duration of treatment / exposure:
- Test duration: 28 days
- Frequency of treatment:
- Dosing regime: 7 days/week
- No. of animals per sex per dose:
- Male: 10 animals at 0 mg/kg bw/day
Male: 5 animals at 50 mg/kg bw/day
Male: 5 animals at 200 mg/kg bw/day
Male: 10 animals at 1000 mg/kg bw/day
Female: 10 animals at 0 mg/kg bw/day
Female: 5 animals at 50 mg/kg bw/day
Female: 5 animals at 200 mg/kg bw/day
Female: 10 animals at 1000 mg/kg bw/day
Examinations
- Observations and examinations performed and frequency:
- Mortality/viability were recorded twice daily.
GENERAL CAGESIDE OBSERVATIONS : twice daily on days 1-3; as well as once daily on days 4-28, and once daily during days 29-42
DETAILED CLINICAL OBSERVATIONS :once weekly (weeks 1 -3)
FOOD CONSUMPTION : once during the pretest period and weekly thereafter
BODY WEIGHTS : weekly
FUNCTIONAL OBSERVATIONAL BATTERY : during week 4
GRIP STRENGTH
LOCOMOTOR ACTIVITY : during the fourth treatment week for a 60-minute period and the total activity of this time period was recorded. - Statistics:
- The following statistical methods were used to analyze the grip strength, locomotor activity, body weight, organ weights and ratios, as well as:
• The Dunnett-test (many to one t-test) based on a pooled variance estimate were applied if the variables could be assumed to follow a normal distribution
for the comparison of the treated groups and the control groups for each sex.
• The Steel-test (many-one rank test) were applied instead of the Dunnett-test when the data can not be assumed to follow a normal distribution.
• Fisher's exact-test were applied to the macroscopic findings.
The following statistical methods were used for statistical analysis of clinical laboratory data:
• Quantitative data were analyzed by a one-way analysis of variance (ANOVA) when the variances are considered homogeneous according to Bartlett.
Alternatively, if the variances are considered to be heterogenous (p<0.05), a non-parametric Kruskal-Wallis test was used. Treated groups were compared
to the control groups using Dunnett's test if the ANOVA was significant at the 5% level and by Dunn's test in the case of a significant Kruskal-Wallis test
(p<0.05).
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Haematological findings:
- no effects observed
- Description (incidence and severity):
- All differences remained within the range of the historical control data and were therefore considered incidental.
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- no effects observed
- Description (incidence and severity):
- dose-related yellow/brown to brown discoloration in males and females treated with 200 mg/kg/day and 1000 mg/kg/day. Considered to be a passive effect of a test item excreted via the renal system, was reversible after the recovery period.
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Description (incidence and severity):
- The mean absolute epididymide weights of males previously treated with 1000 mg/kg/day were significantly higher (p<0.01) when compared with the controls. In the absence of microscopical changes, these findings were considered to be incidental.
- Details on results:
- FUNCTIONAL OBSERVATIONAL BATTERY
No test item-related signs.
Grip Strength :
No changes of toxicological significance were noted in the fore- and hindlimb grip strength at any dose level.
MACROSCOPIC / MICROSCOPIC FINDINGS
The treatment of the males and females with 1000 mg/kg/day was induced the following occasional gross lesions :
bluish discoloration of the mucous membrane of the stomach, of the jejunum, of the ilenum, the cecum and the rectum, the kidneys, the urinary bladder, the testes and epididymides , the uterus and the mammary gland, salivary glands, lacrymal glands, thyroid gland, the mesenteric and mandibular lymph node.
At 200 mg/kg/day, one femal had a bluish discoloration of the kidney and another one had foci in the lungs.
Following the recovery period, all males and/or females treated with 1000 mg/kg/day had black discoloration of the kidney and bluish discoloration of testes and mesenteric lymph node. Ans several animals of one or the other sex gender had a bluish discoloration of the mucous membrane of thestomach.
The microscopical observations revealed that under this experimental conditions, the substance FAT40 815/A induced morphological modifications within the kidneys and lungs. In general, these microscopic modifications were less frequent and less acute than the macroscopic observations noted during the necropsy. At the end of the treatment period, a minimal to slight deposition of pigment was observed in the renal tubular epithelia in all males and females treated with 1000 mg/kg/day. The
The occasional finding of pigment-containing phagocytic cells in the lungs at 200 mg/kg/day was attributed to accidental penetration of the test item into the airways, representing no systemic effect.
Effect levels
open allclose all
- Dose descriptor:
- NOAEL
- Effect level:
- ca. 200 mg/kg bw/day (nominal)
- Sex:
- male/female
- Basis for effect level:
- other: original NCD unit is mg/kg/day.
- Dose descriptor:
- NOEL
- Effect level:
- ca. 50 mg/kg bw/day (nominal)
- Sex:
- male/female
- Basis for effect level:
- other: original NCD unit is mg/kg/day.
Target system / organ toxicity
- Critical effects observed:
- not specified
Applicant's summary and conclusion
- Conclusions:
- Classified as: Not classified
Based on the results of pathology, the no-observed-effect-level (NOEL) of the test item FAT 40'815/A is 50 mg/kg/day. Although the pigment deposition in the renal tubular epithelia at the highest dose did not evoke a local tissue reaction, it was not reversible within the 2-week recovery period. Therefore the no-observed-adverse effect level (NOAEL) of FAT 40'815/A is considered to be 200 mg/kg/day. - Executive summary:
Oral administration of FAT 40'815/A to Wistar rats at doses of 50, 200 and 1000 mg/kg/day, for 28 days resulted in no deaths, no clinical signs of toxicity (during daily or weekly observations), no effects on the parameters of the functional observational battery (performed durnig week 4), no changes in grip strength or locomotor activity, no effects on food consumption or body weight development, no changes in hematology, clinical biochemistry or urinalysis parameters which could be considered to be of toxicological relevance, and no differences in absolute or relative organ weights. There were no late effects after the recovery period.
Test item-related findings were generally restricted to macroscopical effects (passive discoloration of various organs) at 200 mg/kg/day and 1000 mg/kg/day, whereas microscopically, minimal to slight pigment deposition in the renal tubular epithelia of all males and females treated at 1000 mg/kg/day was seen after the treatment and recovery periods.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)
Lai gan ECHA nodrošina Jūsu valodā daudz tiešsaistes dokumentu, daļa no šīs tīmekļa lapas ir pieejama tikai angļu valodā. Lai iegūtu plašāku informāciju par ECHA daudzvalodības praksi, spiediet .
Laipni lūdzam ECHA tīmekļa vietnē! Šī vietne netiek pilnībā atbalstīta programmā Internet Explorer 7 (un agrākās versijās) “Lūdzu, nomainiet to ar jaunāku Internet Explorer versiju.”
Šajā tīmekļa vietnē tiek izmantoti sīkfaili, lai nodrošinātu Jums vislabāko lietojumu mūsu tīmekļa vietnēs.
Uzziniet vairāk par sīkfailu lietošanu.